Steroid-cationic lipid compound and use thereof

MYPI2025006654A0Undetermined Publication Date: 2024-10-29CANSINO (SHANGHAI) BIOLOGICAL RES CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006654
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-29
Filing Date
2024-04-29
Publication Date
2024-10-29

AI Technical Summary

Technical Problem

Existing nucleic acid drug delivery systems, such as LNP, suffer from problems such as complex components, poor stability, and limited applicable routes of administration, especially in the stable storage and nebulized inhalation administration of mRNA-LNP.

Method used

A three-component LNP was prepared by mixing a steroid-cationic lipid compound with auxiliary lipids and polyethylene glycol lipids. This simplified the composition and improved the stability and transfection efficiency, making it suitable for different routes of administration.

Benefits of technology

It achieves efficient and stable nucleic acid delivery, improves the specific antibody response of target cells or organs, has better safety and applicability, and is suitable for nebulized inhalation or dry powder inhalation administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025006654_DRAWING_001
    Figure PI2025006654_DRAWING_001
  • Figure PI2025006654_DRAWING_002
    Figure PI2025006654_DRAWING_002
  • Figure PI2025006654_DRAWING_003
    Figure PI2025006654_DRAWING_003
Patent Text Reader

Abstract

The present invention provides a steroid-cationic lipid compound having a structure represented by formula (I), and use thereof. The compound can be used in the preparation of lipid nanoparticles (LNPs) for delivering a therapeutic agent and / or a prophylactic agent. The LNPs prepared by using the steroid-cationic lipid compound of the present invention have good stability and transfection efficiency. The LNPs are used for delivering nucleic acid, such as mRNA, and can efficiently and stably deliver a bioactive substance to a target cell or organ. In addition, the LNPs have high stability, can be used for developing a freeze-dried preparation of mRNA, can also be used for aerosol inhalation administration of mRNA, and can cause a high specific antibody response in an experimental animal body, and the compound is safer. (I) Fig 1.
Need to check novelty before this filing date? Find Prior Art

Description

A steroid-cationic lipid compound and its application Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to a steroid-cationic lipid compound and its application in the delivery of bioactive substances. Background Art

[0002] Nucleic acid drugs mainly refer to compounds containing nucleotide or deoxynucleotide structures with genetic characteristics and pharmacological activity. They can be used to treat tumors, tissue regeneration, wound healing, pulmonary fibrosis, inflammatory diseases, microbial infections, etc. After nucleic acid drugs are injected into the human body, an efficient and safe drug delivery system is required to deliver them to the lesion site. The drug delivery system needs to stay for a sufficient time to accurately target the lesion site while avoiding damage to normal cells.

[0003] At present, drug delivery systems can be divided into viral vectors and non-viral vectors. Viral vectors are less used in nucleic acid drugs due to their immunogenicity, tumorigenicity, and limited drug loading; non-viral vectors, such as polymers and lipids (liposomes or LNPs), can bind nucleic acid drugs to specific ligands so that they can target specific cells, and are widely used in current nucleic acid drugs. LNP is one of the delivery systems that are currently widely used in nucleic acid drug research. The LNP delivery system can safely and effectively deliver nucleic acids. It has the advantages of high nucleic acid encapsulation rate, ability to effectively transfect cells, strong tissue penetrability, low cytotoxicity and immunogenicity, and has great advantages compared to other drug delivery systems. Therefore, the LNP delivery system has broad development and application prospects.

[0004] In the prior art, LNP delivery systems are often made of ingredients such as ionizable lipids (cationic lipids), steroids, neutral lipids, polyethylene glycol lipids, and nucleic acid drugs. For example: Patent document AU2020325221A1 discloses a composition for delivering LNPs to target cells, comprising (i) ionizable lipids; (ii) sterols or other structured lipids; (iii) non-cationic auxiliary lipids or phospholipids; (iv) PEG lipids and (v) agents encapsulated in LNPs (such as nucleic acid molecules), and these four components are in a specific ratio to enhance the delivery efficiency of target cells; Patent document WO2021 / 250263A1 discloses a composition comprising ionizable lipids, phospholipids, sterols, polyethylene glycol lipids and one or more nucleic acids, and discloses a C14-PEG2000 lipid containing less than about 1 mol%, as well as a specific percentage of other lipids; Patent CN102712935B discloses a lipid particle comprising: cationic lipids; neutral lipids, zwitterionic lipids or anionic lipids; polyethylene glycol lipids; sterols and nucleic acids, and the above components are assembled into lipid particles with a solid core, and the solid core can achieve a higher coating efficiency; Patent document WO 2021 / 055849A1 discloses a lipid having the following structure: This structure can improve its safety, effectiveness and specificity; Patent document WO2021 / 026358Al discloses a target cell delivery lipid nanoparticle (LNP): including (i) ionizable lipids (ii) sterols or other structural lipids; (iii) non-cationic auxiliary lipids or phospholipids; (iv) payload; (v) polyethylene glycol lipids, as a drug delivery system, taking into account both safety and effectiveness. In recent years, it has been discovered that the introduction of cholesterol into ionizable lipid compounds can also be used to deliver nucleic acid drugs. Patent document US7514099B2 discloses a cholesterol amino lipid compound CLinDMA The compound can be combined with phospholipids, cholesterol, and polyethylene glycol lipids to form a four-component LNP or with phospholipids, DMOBA lipids, cholesterol, and PEG lipids to form a five-component LNP to deliver siRNA; Patent document CN112424214A discloses an ionizable cationic lipid compound formed by cholesterol and linear olefins (3) This compound is combined with cholesterol, DPPC, DOPE and DMG-PEG200 to construct lipid nanoparticles to deliver nucleic acids. Both of the above compounds require 4 or even 5 different lipid excipients to form a nucleic acid drug delivery carrier preparation, which is complex to construct. In order to adapt to different application scenarios, it is also particularly important to develop different delivery systems suitable for different routes of administration, such as using aerosol inhalation to treat lung-related diseases or prevent respiratory-related pathogen infections. At present, the stable storage of mRNA-LNP is still a major difficulty. Currently, freeze-drying can achieve stable storage of mRNA-LNP at 2-8°C or even at room temperature. It can be seen that the existing technology optimizes the components in the composition and the cationic lipids. In order to further obtain a safer, more effective, stable, simple to construct LNP delivery system that can be applied to different routes of administration at the same time, it is also necessary to further develop its components and the structure of each component.

[0005] Summary of the Invention

[0006] In a first aspect, the present invention provides a steroid-cationic lipid compound having a structure shown in formula (I):

[0007] wherein said R1 is selected from -OR4, -NR4R5, -NR4C(=O)R5, -C(=O)OR5, -OC(=O)R5, -OC(=O)OR5, -CN, a nitrogen-containing heterocyclic group or a guanidine group;

[0008] Said R4 and R5 are independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or C 3-8 cycloalkynyl;

[0009] The G1 is selected from chemical bonds (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-9 Alkynylidene, C 3-8 Cycloalkylene or C 3-8 cycloalkenylene;

[0010] The number of consecutive carbon atoms in R1-G1- does not exceed 10, for example, the number of consecutive carbon atoms in R1-G1- may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0011] G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene, C 2-12 Alkynylidene, C3-12 Cycloalkylene, C 3-12 Cycloalkenylene, C 3-12 Cycloalkynylene or C 6-12 arylene;

[0012] L1 and L2 are each independently selected from a chemical bond (-), -O-, -S-, -O(C=O)O-, -(C=O)NR a -、-NR a (C=O)-, -O(C=O)-, -(C=O)O-, -SS-, -S(O) x -、-OS(O) x O-, -C(=O)S-, -SC(=O)-, -NR a C(=O)NR b -、-OC(=O)NR a -、-NR a C(=O)O-, -OC(=O)S-, -SC(=O)O-, -P(O)(OR a )O-、-OP(O)(OR a )O- or C 1-12 a combination of one or more of alkylene;

[0013] wherein x is selected from 0, 1 or 2;

[0014] Among them, R a 、R b Each independently selected from H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynes;

[0015] Said R2 is selected from naturally occurring or non-naturally occurring steroids;

[0016] Said R3 is independently selected from naturally occurring or non-naturally occurring steroids, C 6-24 Alkyl, C 6-24 Alkenyl, C 6-24 Alkyne or C 6-24 Alkoxy.

[0017] Furthermore, the R1 is selected from -OR4, -NR4R5, pyrazolyl, imidazolyl, piperazinyl, alkylpiperazine, piperidinyl, alkylpiperidine, guanidinyl, pyrrolyl or pyrrolidinyl; the R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, -C 2-9 Alkynyl, C 3-8 Cycloalkyl or C 3-8 Cycloalkenyl.

[0018] The G1 is a chemical bond (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-8 Cycloalkylene or C 3-8 cycloalkenylene;

[0019] Preferably, the G1 is C 1-6 Alkylene or C 2-6 alkenylene;

[0020] The number of consecutive carbon atoms in R1-G1- does not exceed 10; specifically, the number of consecutive carbon atoms in R1-G1- can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0021] The G2 and G3 are each independently selected from a chemical bond (-), -C 1-12 Alkylene, -C 2-12 Alkenylene or -C 2-12 Alkynylidene;

[0022] The L1 and L2 are each independently selected from -O(C=O)-, -(C=O)O-, -SS-, -O(C=O)O-, -NR a C(=O)O-, -(C=O)NR a -、-NR a (C=O)-, -C(=O)S-, -SC(=O)-, -OC(=O)NR a - or C 1-12 a combination of one or more of alkylene;

[0023] Among them, R a H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynes;

[0024] Further, the R1 is selected from -OR4, -NR4R5, imidazolyl, piperazinyl or guanidinyl;

[0025] Said R4 and R5 are independently selected from H, C 1-5 alkyl;

[0026] The G1 is an unsubstituted C 1-6 alkylene;

[0027] The number of consecutive carbon atoms in R1-G1- does not exceed 10; specifically, the number of consecutive carbon atoms in R1-G1- can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0028] The G2 and G3 are each independently selected from a chemical bond (-), C 1-10 alkylene;

[0029] The L1 and L2 are each independently selected from -O-, -O(C=O)-, -(C=O)O-, -(C=O)S-, -O(C=O)O-, -NHC(=O)O-, -NHC(=O)-,

[0030] Further, the R2 is sterol;

[0031] Preferably, the sterol is an animal sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a plant sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a synthetic sterol, or an oxidized form or a reduced form thereof;

[0032] More preferably, the sterol is selected from cholesterol, an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol;

[0033] More preferably, the sterol is an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol;

[0034] More preferably, the sterol is selected from avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprosterol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fuccasterol, hexahydroluminosterol, hydroxycholesterol; lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid or lithocholic acid;

[0035] More preferably, the structural formula of the sterol is as follows:

[0036] Where R is C 1-20 alkyl.

[0037] Furthermore, the R3 is selected from the following structures:

[0038] Preferably, the R3 is selected from the following structures:

[0039] In one embodiment, the compound of formula (I) is selected from:

[0040] On the other hand, the present invention also provides a lipid nanoparticle comprising the steroid-cationic lipid compound represented by the aforementioned formula (I).

[0041] In one embodiment, the lipid nanoparticle further comprises a polyethylene glycol lipid and at least one helper lipid; the helper lipid is selected from a neutral lipid, a zwitterionic lipid, or an anionic lipid.

[0042] In one embodiment, the polyethylene glycol lipid is selected from 2-[(polyethylene glycol)-2000]-N,N-tetracosylacetamide (ALC-0159), 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE) or PEG-1,2-dimyristoyloxypropyl-3-(PEG-c-DMA);

[0043] and / or,

[0044] The neutral lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), oleoylphosphatidylcholine (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), phosphorylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero oleyl-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1,2-diacaproyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-eicosenoyl-sn-glycero-3-phosphocholine (DEPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), or lysophosphatidylethanolamine.

[0045] In one embodiment, the molar ratio of the steroid-cationic lipid represented by formula (I) to the auxiliary lipid to the polyethylene glycol lipid in the lipid nanoparticles is 20-80:20-80:0.5-20; preferably, the molar ratio of the steroid-cationic lipid represented by formula (I) to the auxiliary lipid to the polyethylene glycol lipid in the lipid nanoparticles is 30-80:30-80:0.5-20; more preferably, the molar ratio of the steroid-cationic lipid represented by formula (I) to the auxiliary lipid to the polyethylene glycol lipid is 40-60:40-60:0.5-5; more preferably, the molar ratio of the steroid-cationic lipid represented by formula (I) to the auxiliary lipid to the polyethylene glycol lipid is 49.25:49.25:1.5.

[0046] In one embodiment, the lipid nanoparticle has a diameter of 15 nm to 300 nm; preferably, the lipid nanoparticle has a diameter of 60 nm to 102 nm; more preferably, the lipid nanoparticle has a diameter of 80 nm to 90 nm.

[0047] In one embodiment, the encapsulation efficiency (%) of the lipid nanoparticles is 80% to 100%.

[0048] In yet another aspect, the present invention further provides a use of the aforementioned steroid-cationic lipid compound and the aforementioned lipid nanoparticles in preparing a bioactive substance delivery system.

[0049] In one embodiment, the bioactive substance can be a small molecule compound, a nucleic acid, an oligopeptide, etc.; preferably, the bioactive substance is a nucleic acid; more preferably, the bioactive substance is DNA or RNA; more preferably, the DNA includes non-coding DNA (antisense DNA) or coding DNA, and / or the RNA includes antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA and self-replicating mRNA.

[0050] In one embodiment, the bioactive substance is used to prevent and / or treat cancer, inflammation, fibrotic diseases, autoimmune diseases, infections, psychiatric disorders, blood diseases, chromosomal diseases, genetic diseases, connective tissue diseases, digestive diseases, ear, nose and throat diseases, endocrine diseases, eye diseases, reproductive diseases, heart diseases, kidney diseases, lung diseases, metabolic diseases, oral diseases, musculoskeletal diseases, newborn screening, nutritional diseases, parasitic diseases, skin diseases, etc.

[0051] In one embodiment, the bioactive substance delivery system is an mRNA vaccine.

[0052] In one embodiment, the mRNA vaccine can be used to prevent cancer, viral infection, bacterial infection, fungal infection, etc. In one embodiment, the viruses include but are not limited to norovirus, Ebola virus, coronavirus (including the new coronavirus SARS-CoV-2), cytomegalovirus, dengue virus, Zika virus, coxsackie virus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, poliovirus, rabies virus, rotavirus, measles virus, etc.

[0053] In yet another aspect, the present invention further provides a lipid nanoparticle comprising the aforementioned lipid nanoparticle and a bioactive substance.

[0054] In one embodiment, the bioactive substance can be a small molecule compound, a nucleic acid, an oligopeptide, etc.; preferably, the bioactive substance is a nucleic acid; more preferably, the bioactive substance is DNA or RNA; more preferably, the DNA includes non-coding DNA (antisense DNA) or coding DNA, and / or the RNA includes antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA and self-replicating mRNA.

[0055] In one embodiment, the nitrogen to phosphorus ratio of the lipid nanoparticles is (1-15): 1. For example, the nitrogen to phosphorus ratio of the lipid nanoparticles can be 1: 1, 1.5: 1, 2: 1, 2.5: 1, 3: 1, 3.5: 1, 4: 1, 4.5: 1, 5: 1, 5.5: 1, 6: 1, 6.5: 1, 7: 1, 7.5: 1, 8: 1, 8.5: 1, 9: 1, 9.5: 1, 10: 1, 10.5: 1, 11: 1, 11.5: 1, 12: 1, 12.5: 1, 13: 1, 13.5: 1, 14: 1, 14.5: 1 or 15: 1; preferably, the nitrogen to phosphorus ratio of the lipid nanoparticles is (2-10): 1; more preferably, the nitrogen to phosphorus ratio of the lipid nanoparticles is (4-8): 1; more preferably, the nitrogen to phosphorus ratio of the composition is 6: 1 or 8: 1.

[0056] On the other hand, the present invention also provides the use of the lipid nanoparticles for preparing mRNA vaccines.

[0057] In one embodiment, the lipid nanoparticles of the present invention can be prepared using conventional methods in the art, such as microfluidics technology.

[0058] In yet another aspect, the present invention further provides a drug comprising the aforementioned bioactive substance and lipid nanoparticles.

[0059] Furthermore, the drug also includes pharmaceutically acceptable excipients.

[0060] Furthermore, the pharmaceutically acceptable excipients of the present invention include, for example, carriers, adjuvants, diluents, and the like.

[0061] Furthermore, the drug of the present invention is a gene drug.

[0062] Furthermore, the medicine of the present invention is a liquid preparation or a lyophilized powder.

[0063] Furthermore, the drug of the present invention is an oral preparation, an intramuscular injection preparation, a subcutaneous injection preparation, an intravenous injection preparation, an aerosol inhalation preparation or a dry powder inhalation preparation.

[0064] In yet another aspect, the present invention further provides a method for delivering a biologically active substance, comprising administering the medicament of the present invention to an individual in need thereof.

[0065] Beneficial effects of the present invention:

[0066] The present invention provides a steroid-cationic lipid compound having a structure represented by formula (I) and its use. This compound, when mixed with a helper lipid and a polyethylene glycol lipid, can be used to prepare lipid nanoparticles for delivering bioactive substances. The three-component LNP prepared using the steroid-cationic lipid compound of the present invention has the advantages of a simple preparation process, good stability, and high transfection efficiency. When used to deliver nucleic acids, such as mRNA, this three-component LNP can efficiently and stably deliver the nucleic acid mRNA to target cells or organs, elicit a high specific antibody response in animals, and have improved safety.

[0067] The three-component LNP prepared using the steroid-cationic lipid compound provided by the present invention exhibits improved stability during the freeze-drying process, making it more suitable for the development and application of mRNA-LNP freeze-dried powder formulations. Furthermore, the three-component LNP prepared using the steroid-cationic lipid compound provided by the present invention retains structural stability and efficient transfection activity after aerosolization, thus showing promising applications in aerosolized inhalation or dry powder inhalation administration of mRNA. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 shows the expression of GFP-mRNA-LNP in Hep3B cells detected by fluorescence microscopy;

[0069] Figure 2 shows the ELISA test of serum antibody titers after mice were immunized with mRNA-LNP;

[0070] Figure 3a shows the CD8 T cell immunophenotype detected by ICS after mice were immunized with mRNA-LNPs;

[0071] Figure 3b shows the CD4 T cell immunophenotype detected by ICS after mice were immunized with mRNA-LNPs;

[0072] Figure 4 shows the expression of serum IL-6 in mice after high-dose administration of mRNA-LNP;

[0073] Figure 5 shows the DLS comparison of LNP before and after atomization;

[0074] FIG6 shows the expression of GFP fluorescent protein detected by fluorescence microscopy after GFP-mRNA-LNP was transfected into Hep3B cells before and after atomization;

[0075] Figure 7a shows images of the body and organs of mice after aerosol inhalation of Luc-mRNA-LNP;

[0076] Figure 7b shows the in vivo and organ imaging of mice after aerosol inhalation of Luc-mRNA-LNP. DETAILED DESCRIPTION

[0077] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.

[0078] definition

[0079] As used in this specification, the following words and phrases are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0080] As used herein, the term "lipid nanoparticle," "Lipid Nanoparticle," or "LNP" refers to a particle having a nanometer size, for example, 1 nm to 1,000 nm, which comprises one or more types of lipid molecules.

[0081] As used herein, the term "gene medicine" generally consists of a vector or delivery system containing an engineered gene construct, the active ingredient of which may be DNA, RNA, genetically modified viruses, bacteria or cells. By introducing exogenous genes into target cells or tissues, it replaces, compensates, blocks or corrects specific genes to achieve the purpose of treating and preventing diseases.

[0082] As used herein, the term "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single- or double-stranded form, and includes DNA, RNA, and hybrids thereof.

[0083] As used herein, the term "lipid compound" or "lipid" refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water but soluble in many organic solvents. The organic solvents of the present invention include, but are not limited to, benzene, toluene, pentane, hexane, methanol, ethanol, isopropanol, ether, ethyl acetate, acetone, and carbon tetrachloride.

[0084] As used herein, the term "alkyl" refers to a saturated straight or branched hydrocarbon group. 1-9 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 1- 8. C 2-7 、C 2-8 、C3-6 or C 4-7 Alkyl; C 6-24 Alkyl groups include straight or branched chain alkyl groups containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms, including, but not limited to, C 6- 8. C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkyl; C 1-5 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4 or 5 carbon atoms, including but not limited to C 1-4 、C 2-4 、C 2-3 、C 3-5 or C 4-5 Alkyl; C 1-20 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, for example, but not limited to C 1-8 、C 1-10 、C 6-22 、C 10-16 or C 14-17 alkyl.

[0085] As used herein, the term "alkenyl" refers to an unsaturated straight or branched hydrocarbon group containing one or more unsaturated carbon-carbon double bonds. The unsaturated carbon-carbon double bond may be present at any stable point along the chain. As used herein, C 2-9 Alkenyl includes straight or branched chain alkenyl groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, including but not limited to C 1-8 、C 2- 7. C 2-8 、C 3-6 or C 4-8 Straight-chain or branched alkenyl; C 6-24 Alkenyl includes straight or branched chain alkenyl groups containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 carbon atoms, for example, but not limited to C 6-8 、C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkenyl.

[0086] As used herein, the term "alkynyl" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon triple bonds. 2-9Alkynyl groups include straight or branched chain alkynyl groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, including but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkynyl.

[0087] As used herein, one or more carbon atoms in alkyl, alkenyl, and alkynyl groups other than the terminal positions may be substituted with heteroatoms such as nitrogen, oxygen, sulfur, and their oxides such as nitrogen oxides, carbonyl, and (oxy)sulfone groups, for example -(CH2) m -O-(CH2) n -、-(CH2) m -S-(CH2) n -、-(CH2) m -SS-(CH2) n -、-(CH2) m -CO-(CH2) n -、-(CH2) m -OCO-(CH2) n -、-(CH2) m -OCOO-(CH2) n -, (wherein m and n can be integers from 1 to 9) can be unsubstituted or substituted with one or more heteroatom substituents as described herein. In certain embodiments, the alkyl, alkenyl or alkynyl group does not include any heteroatoms.

[0088] As used herein, the term "alkylene" refers to a saturated divalent straight or branched hydrocarbon group. 1-9 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkylene; C 1-12 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-12 Alkylene; C 1-10 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C2-8 、C 3-6 or C 4-10 Alkylene; C 1-6 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5 or 6 carbon atoms, for example, but not limited to C 1-5 、C 2-4 、C 3-6 or C 4-6 Alkylene.

[0089] As used herein, the term "alkenylene" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon double bonds. 2-9 Alkenylene includes straight or branched chain alkenylene groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkenylene; C 2-12 The alkenylene group includes straight or branched chain alkenylene groups containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, for example, but not limited to C 2-8 、C 2-7 、C 3-6 or C 4-12 Alkenylene; C 2-6 Alkenylene includes straight or branched chain alkenylene groups containing 2, 3, 4, 5 or 6 carbon atoms, for example, but not limited to C 2-5 、C 2-4 、C 3-6 or C 4-6 Alkenylene.

[0090] As used herein, the term "alkynylene" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon triple bonds. 2-12 Alkyne groups include straight or branched chain alkynylene groups containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including, but not limited to, C 2-8 、C 2-7 、C 3-6 or C 4-12 Alkynylidene; C 3-9 Alkyne groups include straight or branched chain alkynylene groups containing 3, 4, 5, 6, 7, 8, or 9 carbon atoms, including, but not limited to, C 3-6 、C 3- 8 or C 4-7 Alkynylidene.

[0091] As used herein, alkylene, alkenylene or alkynylene can comprise one or more cyclic aliphatic groups and / or one or more heteroatoms such as oxygen, nitrogen or sulphur, and can optionally be replaced by one or more substituents such as alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester or amide. Remove the end group position, one or more carbons at other positions can be replaced by heteroatoms such as nitrogen, oxygen, sulphur and oxides thereof such as nitrogen oxide, carbonyl, sulfone or sulfoxide. In certain embodiments, alkylene, alkenylene or alkynylene are unsubstituted. In certain embodiments, alkylene, alkenylene or alkynylene do not include any heteroatoms.

[0092] As used herein, the term "nitrogen-containing heterocyclic group" refers to a heterocyclic group containing a nitrogen atom in its structure, including but not limited to substituted or unsubstituted: aziridinyl, azetidinyl, β-propiolactam, pyrrolyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, caprolactam, pyranyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, piperazinyl, indolyl, benzimidazolyl, carbazolyl, quinolyl, isoquinolyl, pteridinyl, acridinyl, 7H-purinyl, phenazinyl, phenothiazinyl or 1H-aza base.

[0093] As used herein, the term "alkoxy" refers to an "alkyl-O-" group, wherein alkyl is as defined herein. As used herein, C 6-24 Alkoxy includes straight or branched chain alkoxy containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 carbon atoms, for example, but not limited to C 6-8 、C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkoxy.

[0094] As used herein, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon group. 3-8 Cycloalkyl groups include cycloalkyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example, but not limited to C 3-7 、C 4-7 or C 3-6 Cycloalkyl.

[0095] As used herein, the term "cycloalkenyl" refers to a cyclic hydrocarbon group containing at least one carbon-carbon double bond. 3-8 Cycloalkenyl groups include cycloalkenyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4- 7 or C 3-6 Cycloalkenyl.

[0096] As used herein, the term "cycloalkynyl" refers to a cyclic hydrocarbon group containing at least one carbon-carbon triple bond. 3-8 Cycloalkynyl groups include cycloalkynyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4-7 or C 3-6 Cycloalkynyl.

[0097] As used herein, the term "cycloalkylene" refers to a divalent cycloalkyl group that is used to link two structures together. 3-12 Cycloalkylene includes cycloalkylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkylene; C 3-8 Cycloalkylene includes cycloalkyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkylene.

[0098] As used herein, the term "cycloalkenylene" refers to a divalent cycloalkenyl group that is used to link two structures together. 3-12 Cycloalkenylene groups include cycloalkenylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkenylene; C 3-8 Cycloalkenylene includes cycloalkenylene containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkenylene.

[0099] As used herein, the term "cycloalkynylene" refers to a divalent cycloalkynyl group that is used to link two structures together. 3-12 Cycloalkynylene groups include cycloalkynylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkynylene; C 3-8Cycloalkynylene groups include cycloalkynylene groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example, including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkynylene.

[0100] As used herein, the term "arylene" refers to a divalent aromatic group that is used to link two structures together, wherein aryl includes monocyclic aromatic groups (having, for example, 4n+2 delocalized electrons) and polycyclic aromatic groups. As used herein, C 6-12 Arylene groups include those containing 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 6-8 、C 6-9 、C 6-12 Arylene.

[0101] As used herein, the term "cationic lipid" refers to a lipid molecule that is capable of becoming positively charged in response to environmental pH or hydrogen ion activity.

[0102] As used herein, the term "helper lipid" refers to a lipid that is not positively charged under ambient pH conditions, and includes neutral lipids that are not charged, zwitterionic lipids, and negatively charged anionic lipids.

[0103] As used herein, the term "PEGylated lipid" refers to a lipid molecule comprising a lipid portion and a polyethylene glycol portion.

[0104] As used herein, the term "delivery system" refers to a formulation or composition that regulates the spatial, temporal, and dosage distribution of a biologically active ingredient in an organism.

[0105] It should be noted that the methods used in the present invention, unless otherwise specified, are all conventional methods, and the reagents used in the present invention, unless otherwise specified, are all commercially available products.

[0106] Example

[0107] Example 1 Synthesis of Compound 1

[0108] Step 1: Synthesis of 6-bromohexyl 2-hexyldecanoate (1a)

[0109] 2-Hexyldecanoic acid (2.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 6-bromohexanol (0.93 g, 5.0 mmol), 4-dimethylaminopyridine (DMAP, 0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCL (1.10 g, 6.0 mmol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 1a (1.45 g, light yellow oil) with a yield of 70%.

[0110] MS m / z(ESI):419.2[M+1]

[0111] Step 2: Synthesis of 6-((4-hydroxybutyl)amino)hexyl 2-hexyldecanoate (1b)

[0112] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 4-amino-1-butanol (4.00 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 1b (1.13 g, light yellow oil).

[0113] MS m / z(ESI):428.4[M+1]

[0114] Step 3: Synthesis of 6-bromohexyl cholesteryl carbonate (1c)

[0115] 6-Bromohexanol (0.91 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches. The reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain product 1c (1.83 g, light yellow oil) with a yield of 62%.

[0116] MS m / z(ESI):593.3[M+1]

[0117] Step 4: Synthesis of compound 1

[0118] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 1 (470 mg, light yellow oil) in a 50% yield.

[0119] MS m / z(ESI):941.4[M+1]

[0120] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,4H),3.67-3.61( m,2H),3.58-3.50(m,2H),2.47-2.42(m,8H),2.03-1.72(m,5H),1.67-0.85(m,82H),0.70(s,3H)

[0121] Example 2 Synthesis of Compound 2

[0122] 6-Bromohexyl cholesteryl carbonate 1c (1.48 g, 2.5 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-amino-1-butanol (89.2 mg, 1.0 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 2 (679 mg, light yellow solid) in a 61% yield.

[0123] MS m / z(ESI):1115.2[M+1]

[0124] 1H NMR (300MHz, CDCl3): δ5.40(t,2H,J=5.4Hz), 4.53-4.40(m,2H), 4.15(t,4H,J=5.6Hz), 3.76(t,2H,J=5.4Hz), 3.20-3.01(m,6H),2.45-2.31(m,4H),2.02-1.75(m,16H),1.74-1.22(m,36H),1.19-0.87(m,44H),0.70(s,6H)

[0125] Example 3 Synthesis of Compound 3

[0126] Step 1: Synthesis of 6-((2-(dimethylamino)ethyl)amino)hexyl 2-hexyldecanoate (3a)

[0127] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and N,N-dimethylethylenediamine (4.00 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain compound 3a (1.20 g, light yellow oil).

[0128] MS m / z(ESI):427.4[M+1]

[0129] Step 2: Synthesis of compound 3

[0130] 6-((2-(Dimethylamino)ethyl)amino)hexyl 2-hexyldecanoate 3a (426 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 3 (517 mg, light yellow oil) in a 55% yield.

[0131] MS m / z(ESI):940.0[M+1]

[0132] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,3H),3.76-3.61( m,2H),3.45-3.38(m,3H),2.94-2.85(m,1H),2.55-2.27(m,5H),2.03-0.85(m,70H),0.70(s,3H)

[0133] Example 4 Synthesis of Compound 4

[0134] Step 1: Synthesis of 6-((2-hydroxyethyl)amino)hexyl 2-hexyldecanoate (4a)

[0135] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and ethanolamine (2.75 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 4a (1.01 g, light yellow oil).

[0136] MS m / z(ESI):400.4[M+1]

[0137] Step 2: Synthesis of compound 4

[0138] 6-((2-Hydroxyethyl)amino)hexyl 2-hexyldecanoate 4a (400 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 4 (474 ​​mg, light yellow oil) in a 52% yield.

[0139] MS m / z(ESI):913.1[M+1]

[0140] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,4H),3.67-3.61( m,2H),3.58-3.50(m,4H),2.47-2.42(m,2H),2.03-1.72(m,5H),1.67-0.85(m,82H),0.70(s,3H)

[0141] Example 5 Synthesis of Compound 5

[0142] Step 1: Synthesis of 2-hexyldecyl 8-bromooctanoate (5a)

[0143] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 2-hexyldecanol (1.21 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 5a (1.52 g, light yellow oil) in a yield of 68%.

[0144] MS m / z(ESI):447.2[M+1]

[0145] Step 2: Synthesis of 2-hexyldecyl 8-((4-hydroxybutyl)amino)octanoate (5b)

[0146] At room temperature, 2-hexyldecyl 8-bromooctanoate 5a (1.34 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 5b (1.21 g, light yellow oil).

[0147] MS m / z(ESI):456.4[M+1]

[0148] Step 3: Synthesis of 8-bromooctanoic acid cholesterol ester (5c)

[0149] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane. Cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC-HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 5c (1.77 g, light yellow oil) in a 60% yield.

[0150] MS m / z(ESI):591.4[M+1]

[0151] Step 4: Synthesis of compound 5

[0152] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 8-bromooctanoate 5c (708 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 5 (464 mg, light yellow oil) in a 48% yield.

[0153] MS m / z(ESI):967.6[M+1]

[0154] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3.67 -3.61(m,2H),2.64(t,6H,J=5.4Hz),2.37-2.25(m,6H),2.10-0.85(m,93H),0.70(s,3H)

[0155] Example 6 Synthesis of Compound 6

[0156] Step 1: Synthesis of 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate (6a)

[0157] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)imidazole (5.63 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 6a (1.46 g, light yellow oil).

[0158] MS m / z(ESI):464.4[M+1]

[0159] Step 2: Synthesis of compound 6

[0160] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 6 (517 mg, light yellow oil) in a 53% yield.

[0161] MS m / z(ESI):976.9[M+1]

[0162] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,5H),2.47-2.30(m,9H),2.36-0.85(m,87H),0.70(s,3H)

[0163] Example 7 Synthesis of Compound 7

[0164] Step 1: Synthesis of 6-bromohexylundecylcarbamate (7a)

[0165] 6-Bromohexanol (0.91 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. Undecylamine (0.96 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 7a (1.23 g, light yellow oil) with a yield of 65%.

[0166] MS m / z(ESI):378.2[M+1]

[0167] Step 2: Synthesis of 6-((4-hydroxybutyl)amino)undecylcarbamate (7b)

[0168] At room temperature, 6-bromohexylundecylcarbamate 7a (1.13 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 7b (1.14 g, light yellow oil).

[0169] MS m / z(ESI):387.4[M+1]

[0170] Step 3: Synthesis of compound 7

[0171] 6-((4-Hydroxybutyl)amino)undecylcarbamic acid hexyl ester 7b (386 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 7 (459 mg, light yellow oil) in a 51% yield.

[0172] MS m / z(ESI):900.4[M+1]

[0173] 1H NMR (300MHz, CDCl3): δ5.42(t,1H,J=5.4Hz),4.80-4.71(m,1H),4.51-4.40(m,1H),4.20-4.02(m,4H),3. 75-3.61(m,2H),3.20-3.11(m,2H),2.91-2.73(m,5H),2.43-2.36(m,2H),2.10-0.83(m,79H),0.70(s,3H)

[0174] Example 8 Synthesis of Compound 8

[0175] Step 1: Synthesis of S-undecyl 8-bromooctane sulfate (8a)

[0176] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and undecanethiol (0.94 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC-HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 8a (1.30 g, light yellow oil) in a 66% yield.

[0177] MS m / z(ESI):393.2[M+1]

[0178] Step 2: Synthesis of S-undecyl 8-((4-hydroxybutyl)amino)octylthioate (8b)

[0179] At room temperature, S-undecyl 8-bromooctane sulfate 8a (1.18 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50 ° C. and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45 ° C. The crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 8b (1.18 g, light yellow oil).

[0180] MS m / z(ESI):402.3[M+1]

[0181] Step 3: Synthesis of compound 8

[0182] S-Undecyl 8-((4-hydroxybutyl)amino)octanethioate 8b (401 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 8 (458 mg, light yellow oil) in a 50% yield.

[0183] MS m / z(ESI):914.9[M+1]

[0184] 1H NMR (300MHz, CDCl3): δ5.42 (t, 1H, J = 5.4Hz), 4.51-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3.6 5-3.51(m,2H),2.91-2.83(m,2H),2.60-2.36(m,10H),2.10-0.86(m,82H),0.70(s,3H)

[0185] Example 9 Synthesis of Compound 9

[0186] Step 1: Synthesis of 6-((4-((tert-Butoxycarbonyl)amino)butyl)amino)hexyl 2-hexyldecanoate (9a)

[0187] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and BOC-1,4-butanediamine hydrochloride (10.1 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 9a (1.51 g, light yellow oil).

[0188] MS m / z(ESI):527.5[M+1]

[0189] Step 2: Synthesis of compound 9b

[0190] 6-((4-((tert-Butoxycarbonyl)amino)butyl)amino)hexyl 2-hexyldecanoate 9a (526 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 9b (540 mg, light yellow oil) in a 52% yield.

[0191] MS m / z(ESI):1039.9[M+1]

[0192] Step 3: Synthesis of compound 9

[0193] Compound 9b (1.04 g, 1.0 mmol) was dissolved in dichloromethane. A solution of trifluoroacetic acid in dichloromethane was added under ice-cooling, and the mixture was stirred at room temperature for 16 h. The trifluoroacetic acid was removed by rotary evaporation, and the mixture was dissolved in dichloromethane. The mixture was washed twice with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 9 (460 mg, light yellow oil) in a 49% yield.

[0194] MS m / z(ESI):940.1[M+1]

[0195] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.63-4.40 (m, 1H), 4.19-4.03 (m ,4H),2.79-2.70(m,2H),2.55-2.28(m,10H),2.02-0.87(m,89H),0.70(s,3H)

[0196] Example 10 Synthesis of Compound 10

[0197] Step 1: Synthesis of 4-bromobutyl cholesteryl carbonate (10a)

[0198] 4-Bromobutanol (0.77 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. P-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was then added in batches. The reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give product 10a (1.50 g, light yellow oil) in a yield of 53%.

[0199] MS m / z(ESI):565.3[M+1]

[0200] Step 2: Synthesis of compound 10

[0201] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 10a (678 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 10 (455 mg, light yellow oil) in a 48% yield.

[0202] MS m / z(ESI):948.9[M+1]

[0203] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,6H),2.47-2.30(m,8H),2.36-0.85(m,83H),0.70(s,3H)

[0204] Example 11 Synthesis of Compound 11

[0205] Step 1: Synthesis of 2-bromoethyl cholesteryl carbonate (11a)

[0206] 2-Bromoethanol (0.63 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain product 11a (1.53 g, light yellow oil) with a yield of 57%.

[0207] MS m / z(ESI):537.3[M+1]

[0208] Step 2: Synthesis of compound 11

[0209] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 2-bromoethyl cholesteryl carbonate 11a (644 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 11 (506 mg, light yellow oil) in a yield of 55%.

[0210] MS m / z(ESI):920.8[M+1]

[0211] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5.4Hz), 4. 53-4.40(m,1H),4.20-3.95(m,6H),2.74-2.365(m,2H),2.47-2.30(m,6H),2.36-0.85(m,79H),0.70(s,3H)

[0212] Example 12 Synthesis of Compound 12

[0213] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 10a (679 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 12 (566 mg, light yellow oil) in a 62% yield.

[0214] MS m / z(ESI):913.0[M+1]

[0215] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 4H), 3. 67-3.61(m,2H),2.63-2.32(m,8H),2.03-1.72(m,5H),1.67-0.85(m,80H),0.70(s,3H)

[0216] Example 13 Synthesis of Compound 13

[0217] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 11a (645 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 13 (451 mg, light yellow oil) in a 51% yield.

[0218] MS m / z(ESI):885.1[M+1]

[0219] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.29-4.21(m,2H),4.20-4.02(m,2H),3. 67-3.61(m,2H),2.85-2.78(m,2H),2.63-2.32(m,6H),2.03-1.72(m,5H),1.67-0.85(m,76H),0.70(s,3H)

[0220] Example 14 Synthesis of Compound 14

[0221] Step 1: Synthesis of 2-(hexyloxy)-1-(pentyloxy)ethyl 7-bromoheptanoate (14a)

[0222] 7-Bromoheptanoic acid (1.05 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 2-(hexyloxy)-1-(pentyloxy)-1-ethanol (1.16 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 14a (1.08 g, light yellow oil) in a yield of 51%.

[0223] MS m / z(ESI):423.2[M+1]

[0224] Step 2: Synthesis of 2-(hexyloxy)-1-(pentyloxy)ethyl 7-((4-hydroxybutyl)amino)heptanoate (14b)

[0225] At room temperature, 2-(hexyloxy)-1-(pentyloxy)ethyl 7-bromoheptanoate 14a (1.27 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 14b (1.05 g, light yellow oil).

[0226] MS m / z(ESI):432.4[M+1]

[0227] Step 3: Synthesis of compound 14

[0228] 2-(Hexyloxy)-1-(pentyloxy)ethyl 7-((4-hydroxybutyl)amino)heptanoate 14b (432 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 8-bromooctanoate 5c (708 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to afford compound 14 (490 mg, light yellow oil) in a 52% yield.

[0229] MS m / z(ESI):942.8[M+1]

[0230] 1H NMR (300MHz, CDCl3): δ6.67 (t, 1H, J = 6.3Hz), 5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3. 67-3.61(m,2H),3.47-3.31(m,4H),2.64(t,6H,J=5.4Hz),2.37-2.25(m,6H),2.10-0.85(m,80H),0.70(s,3H)

[0231] Example 15 Synthesis of Compound 15

[0232] Step 1: Synthesis of heptadecan-9-yl 3-oxopropanoate (15a)

[0233] 3-Oxopropionic acid (0.44 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and 9-heptadecanol (1.28 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 15a (0.78 g, light yellow oil) in a 48% yield.

[0234] MS m / z(ESI):327.3[M+1]

[0235] Step 2: Synthesis of heptadecan-9-yl 3-hydroxypropionate (15b)

[0236] Heptadecan-9-yl 3-oxopropanoate 15a (0.78 g, 2.3 mmol) was dissolved in 10 mL of n-butanol, and sodium borohydride (266 mg, 7 mmol) was added at 0°C. The mixture was stirred at room temperature for 12 h, and the reaction progress was monitored. After the starting material was completely consumed, a saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15b (0.70 g, light yellow oil).

[0237] MS m / z(ESI):329.3[M+1]

[0238] Step 3: Synthesis of compound 15c

[0239] 3-Bromopropionic acid (306 mg, 2.0 mmol) was dissolved in 10 mL of dichloromethane. Heptadecyl-9-yl 3-hydroxypropionate 15b (658 mg, 2.0 mmol), DMAP (84 mg, 0.8 mmol), and triethylamine (248 mg, 2.4 mmol) were added and stirred to dissolve. A solution of EDC-HCl (440 mg, 2.4 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 15c (528 mg, light yellow oil) in a 57% yield.

[0240] MS m / z(ESI):463.2[M+1]

[0241] Step 4: Synthesis of compound 15d

[0242] At room temperature, compound 15c (528 mg, 1.14 mmol) was dissolved in 10 mL of ethanol, butanolamine (1.5 g, 17 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15d (480 mg, light yellow oil).

[0243] MS m / z(ESI):472.4[M+1]

[0244] Step 5: Synthesis of compound 15e

[0245] 3-Oxopropionic acid (0.44 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCL (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 15a (1.03 g, light yellow oil) in a yield of 45%.

[0246] MS m / z(ESI):456.4[M+1]

[0247] Step 6: Synthesis of compound 15f

[0248] Compound 15e (1.03 g, 2.2 mmol) was dissolved in 10 mL of n-butanol, and sodium borohydride (266 mg, 7 mmol) was added at 0°C. The mixture was stirred at room temperature for 12 h. The reaction progress was monitored. After the starting material was completely consumed, saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15f (980 mg, light yellow oil).

[0249] MS m / z(ESI):459.4[M+1]

[0250] Step 7: Synthesis of compound 15g

[0251] 3-Bromopropionic acid (306 mg, 2.0 mmol) was dissolved in 10 mL of dichloromethane, and compound 15f (916 mg, 2.0 mmol), DMAP (84 mg, 0.8 mmol), and triethylamine (248 mg, 2.4 mmol) were added and stirred to dissolve. A solution of EDC-HCl (440 mg, 2.4 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 15g (629 mg, light yellow oil) in a 53% yield.

[0252] MS m / z(ESI):593.3[M+1]

[0253] Step 8: Synthesis of compound 15

[0254] Compound 15d (480 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 15g (600 mg, 1.1 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 15 (384 mg, light yellow oil) in a 39% yield.

[0255] MS m / z(ESI):984.8[M+1]

[0256] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.30(m,6H),3.77-3.71(m,4H),3.47-3.31( m,2H),3.12-3.05(m,2H),2.68-2.60(m,8H),2.37-2.25(m,6H),2.10-0.85(m,72H),0.70(s,3H)

[0257] Example 16 Synthesis of Compound 16

[0258] Step 1: Synthesis of compound 16a

[0259] 2-Hexyldecanoic acid (1.28 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and bis(2-hydroxyethyl) disulfide (1.54 g, 10.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC-HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 16a (1.00 g, light yellow oil) was obtained by column chromatography in a 51% yield.

[0260] MS m / z(ESI):393.2[M+1]

[0261] Step 2: Synthesis of compound 16b

[0262] Compound 16a (1.00 g, 2.5 mmol) was dissolved in 20 mL of dichloromethane, and triethylamine (0.76 g, 7.5 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and methylsulfonyl chloride (0.72 g, 6.2 mmol) was added. The mixture was stirred at room temperature for 16-20 hours. After the reaction was complete, the mixture was washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16b (1.00 g, a light yellow oil) in an 85% yield.

[0263] MS m / z(ESI):471.2[M+1]

[0264] Step 3: Synthesis of compound 16c

[0265] Compound 16b (1.00 g, 2.0 mmol) was dissolved in 20 mL of acetonitrile, and potassium carbonate (0.83 g, 6.0 mmol) and 4-aminobutanol (0.18 g, 2.0 mmol) were added. The mixture was stirred at room temperature for 16-20 h. After completion of the reaction, the mixture was filtered through Celite, and the filtrate was added with dichloromethane. The mixture was washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16c (658 mg, light yellow oil) in a 71% yield.

[0266] MS m / z(ESI):464.3[M+1]

[0267] Step 4: Synthesis of compound 16d

[0268] Cholesterol (1.93 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. To the reaction solution was added bis(2-hydroxyethyl) disulfide (0.86 g, 5.6 mmol), and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give product 16d (1.45 g, light yellow oil) in a yield of 51%.

[0269] MS m / z(ESI):567.4[M+1]

[0270] Step 5: Synthesis of compound 16e

[0271] Compound 16d (1.42 g, 2.5 mmol) was dissolved in 20 mL of dichloromethane, and triethylamine (0.76 g, 7.5 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and methylsulfonyl chloride (0.72 g, 6.2 mmol) was added. The mixture was stirred at room temperature for 16-20 h. After the reaction was complete, the mixture was washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16e (1.26 g, a light yellow oil) in a 78% yield.

[0272] MS m / z(ESI):645.3[M+1]

[0273] Step 6: Synthesis of compound 16

[0274] Compound 16e (1.26 g, 2.0 mmol) was dissolved in 20 mL of acetonitrile, and potassium carbonate (0.83 g, 6.0 mmol) and compound 16c (0.93 g, 2.0 mmol) were added. The mixture was stirred at room temperature for 16-20 h. After completion of the reaction, the mixture was filtered through Celite. The filtrate was added with dichloromethane and washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography afforded compound 16 (871 mg, light yellow oil) in a 43% yield.

[0275] MS m / z(ESI):1012.7[M+1]

[0276] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,4H),3.67-3.61( m,2H),3.58-3.50(m,2H),2.47-2.42(m,8H),2.03-1.72(m,5H),1.67-0.85(m,74H),0.70(s,3H)

[0277] Example 17 Synthesis of Compound 17

[0278] Step 1: Synthesis of compound 17a

[0279] 4-Bromobutyric acid (0.84 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.94 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 17a (1.68 g, light yellow oil) in a 63% yield.

[0280] MS m / z(ESI):535.3[M+1]

[0281] Step 2: Synthesis of compound 17

[0282] Compound 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 17a (643 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 17 (505 mg, light yellow oil) in a 55% yield.

[0283] MS m / z(ESI):918.9[M+1]

[0284] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (s, 1H), 6.94 (s, 1H), 5.40 (t, 1H, J = 5.4Hz), 4. 53-4.40(m,1H),4.10-3.92(m,4H),2.48-2.25(m,11H),2.10-0.85(m,80H),0.70(s,3H)

[0285] Example 18 Synthesis of Compound 18

[0286] Step 1: Synthesis of compound 18a

[0287] 2-Hexyldecanoic acid (2.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 6-bromohexylamine hydrochloride (1.09 g, 5.0 mmol), HATU (2.28 g, 6.0 mmol), and DIPEA (1.29 g, 10.0 mmol) were added and stirred at room temperature for 16 hours. The mixture was quenched with water, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the layers were separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 18a (1.40 g, light yellow oil) in a 67% yield.

[0288] MS m / z(ESI):418.3[M+1]

[0289] Step 2: Synthesis of compound 18b

[0290] At room temperature, compound 18a (1.25 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)imidazole (5.63 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane. The product was washed three times with saturated brine, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 18b (1.42 g, light yellow oil).

[0291] MS m / z(ESI):463.4[M+1]

[0292] Step 3: Synthesis of compound 18c

[0293] 1,4-Dibromobutane (2.16 g, 10.0 mmol) was dissolved in 30 mL of n-butanol, and cholesterol (1.94 g, 5.0 mmol) and sodium hydroxide (1.20 g, 30 mmol) were added. The mixture was heated under reflux with stirring for 5 h. After completion of the reaction, dilute hydrochloric acid was added to adjust the pH to neutral. The n-butanol was removed, and the mixture was diluted with 20 mL of dichloromethane. The mixture was then washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography afforded product 18c (1.25 g, light yellow oil) in a 48% yield.

[0294] MS m / z(ESI):521.3[M+1]

[0295] Step 4: Synthesis of compound 18

[0296] Compound 18b (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 18c (625 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 18 (434 mg, light yellow oil) in a 48% yield.

[0297] MS m / z(ESI):903.9[M+1]

[0298] 1H NMR (300MHz, CDCl3): δ8.01(s,1H),7.49(s,1H),7.08(s,1H),6.94(s,1H),5.40(t,1H,J=5.4Hz),4.10-3 .92(m,2H),3.35(t,2H,J=5.4Hz),3.28-3.01(m,7H),2.50-2.42(m,4H),2.10-0.85(m,83H),0.70(s,3H)

[0299] Example 19 Synthesis of Compound 19

[0300] Step 1: Synthesis of compound 19a

[0301] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)-4-methylpiperazine (7.07 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 19a (1.49 g, light yellow oil).

[0302] MS m / z(ESI):496.5[M+1]

[0303] Step 2: Synthesis of compound 19

[0304] Compound 19a (496 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 11a (646 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 hours. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 19 (543 mg, light yellow oil) in a 57% yield.

[0305] MS m / z(ESI):952.9[M+1]

[0306] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-3.95 ( m,6H),2.74-2.65(m,2H),2.47-2.40(m,6H),2.36-0.85(m,90H),0.70(s,3H)

[0307] Example 20 Synthesis of Compound 20

[0308] Step 1: Synthesis of compound 20a

[0309] 4-Bromobutanol (0.77 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. β-Sitosterol (2.32 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain product 20a (1.63 g, light yellow oil) in a yield of 55%.

[0310] MS m / z(ESI):593.3[M+1]

[0311] Step 2: Synthesis of compound 20

[0312] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 20a (713 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 20 (547 mg, light yellow oil) in a yield of 56%.

[0313] MS m / z(ESI):976.9[M+1]

[0314] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,6H),2.47-2.30(m,8H),2.36-0.85(m,87H),0.70(s,3H)

[0315] Example 21 Synthesis of Compound 21

[0316] Step 1: Synthesis of compound 21a

[0317] 6-Bromohexanoic acid (0.975 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 21a (1.92 g, light yellow oil) in a 68% yield.

[0318] MS m / z(ESI):563.4[M+1]

[0319] Step 2: Synthesis of compound 21

[0320] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 6-bromohexanoate 21a (676 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 21 (422 mg, light yellow oil) in a 45% yield.

[0321] MS m / z(ESI):938.9[M+1]

[0322] 1H NMR (400MHz, CDCl3) δ5.27(tt,J=12.5,2.0Hz,1H),4.64(p,J=14.8Hz,1H),4.31(ddd,J=103.0,24.8,14.1Hz,2H),3.46(t,J=14 .8Hz,2H),2.78–2.63(m,6H),2.44–2.27(m,4H),2.27–1.47(m,21H),1.45–1.15(m,47H),1.15–0.96(m,4H),0.95–0.83(m,21H).

[0323] Example 22 Synthesis of Compound 24

[0324] Compound 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 18c (625 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 24 (470 mg, light yellow oil) in a 52% yield.

[0325] MS m / z(ESI):904.9[M+1]

[0326] 1H NMR(400MHz, CDCl3)δ7.92(s,1H),7.24–6.71(m,2H),5.27(tt,J=12.5,2.0Hz,1H),4.17–3.98(m,4H),3.57–3 .31(m,3H),2.79–2.63(m,4H),2.47–2.38(m,4H),2.37–1.77(m,7H),1.75–1.00(m,58H),0.96–0.81(m,21H).

[0327] Example 23 Synthesis of Compound 25

[0328] Step 1: Synthesis of compound 25a

[0329] 4-Bromobutyric acid (0.835 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC-HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 25a (1.90 g, light yellow oil) in a yield of 71%.

[0330] MS m / z(ESI):535.4[M+1]

[0331] Step 2: Synthesis of compound 25

[0332] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 4-bromobutyrate 21a (643 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 25 (373 mg, light yellow oil) in a 41% yield.

[0333] MS m / z(ESI):910.9[M+1]

[0334] 1H NMR(400MHz, CDCl3) δ5.27(tt,J=12.5,2.0Hz,1H),4.68(p,J=14.8Hz,1H),4 .31(ddd,J=103.0,24.8,13.0Hz,2H),3.46(t,J=14.8Hz,2H),2.79–2.62(m, 4H),2.43(td,J=12.2,6.0Hz,4H),2.37–2.11(m,3H),2.11–1.80(m,9H),1.7 9–1.46(m,11H),1.45–1.15(m,43H),1.14–0.98(m,4H),0.97–0.80(m,21H).

[0335] Example 24: Encapsulation of mRNA by a three-component LNP composition and characterization of LNP-mRNA

[0336] Taking GFP mRNA as an example, the construction of a steroid-cationic lipid three-component LNP-mRNA vaccine was demonstrated: the lipid compound of the present invention, the auxiliary lipid, and the polyethylene glycol lipid were dissolved in an ethanol solution according to the molar ratio of Table 1 to obtain a lipid mixture, the mRNA was dissolved in a pH 4.0 acetate buffer, and the lipid mixture and mRNA were passed through the microfluidic device Precision Nanosystems' nanoparticle preparation instrument Ignite at a flow rate ratio of 1:3 to prepare an mRNA-LNP composition (see Table 1 for the specific formula). The packaged mRNA-LNP was dialyzed and ultrafiltered into DPBS, and samples for subsequent animal experiments were obtained after sterile filtration. Sampling was tested for encapsulation efficiency, average particle size, PDI, and Zeta potential.

[0337] Table 1 Lipid formula molar percentage and nitrogen-phosphorus ratio of three-component LNPs formed by steroid-cationic lipid compounds

[0338] Among them, patent CN112424214A compound (1)

[0339] Patent CN112424214A compound (2)

[0340] Patent CN112424214A compound (3)

[0341] Patented US7514099B2 compound (CLinDMA):

[0342] As shown in Table 2, the results show that the composition formed by the steroid-cationic lipid of the present invention and the auxiliary phosphate, polyethylene glycol lipid and mRNA has good physical and chemical properties, such as an average particle size between 60-100nm, a PDI of less than 0.2, and a good polydispersity coefficient; a zeta potential of between ±10mV, with a small weak electric property; and an encapsulation efficiency of more than 85%. The PDI and mRNA encapsulation efficiency of the three-component lipid nanoparticle formula provided by the present invention are better than those of the lipid nanoparticle formula made from the lipid compounds provided by CN112424214A and US7514099B2. The LNP made from a compound with a branched structure has a higher encapsulation efficiency for mRNA than the LNP (LNP7 and LNP8) made from a compound with a straight chain structure. This proves that the three-component LNP made from the steroid-cationic lipid compound provided by the present invention can achieve efficient encapsulation of mRNA.

[0343] Table 2 Characterization parameters of the three-component GFP-mRNA-LNP composition formed by steroid-cationic lipid compound

[0344] Example 25: Cellular experiments with mRNA-LNPs compositions encoding GFP

[0345] The cell density was 6.5 × 10 5 Hep3B cells at a concentration of 1 mL / well were seeded into 24-well cell culture plates. After 24 hours, 500 ng of GFP mRNA-LNP (prepared in Example 24) was transfected per well, and the cell culture plates were placed in a 37°C, 5% CO2 cell culture incubator. The negative control group was transfected with an equal volume of normal saline. After 24 hours, microscopic imaging was performed, and the results are shown in Figure 1. The results show that the three-component LNP composition formed by the steroid-cationic lipid compound of the present invention can achieve high expression of GFP-mRNA in cells, and the expression level is significantly higher than that of the control group. Among them, the LNP composed of a compound with a branched fatty chain structure has a higher encapsulation and delivery efficiency for mRNA than the compound with a linear fatty chain structure. The possible reason is that this branched structure makes it easier for the lipid layer to transform from a lamellar phase to an inverted hexagonal phase, thereby facilitating the release of mRNA and improving the transfection efficiency.

[0346] Example 26: Animal Immunization Test of SARS-CoV-2 Antigen mRNA-LNP Composition

[0347] SARS-CoV-2 S protein antigen mRNA was used to prepare SARS-CoV-2 antigen mRNA-LNPs according to the lipid formulation in Table 1 of Example 24. Six- to eight-week-old female BALB / c mice were randomly divided into groups of 5 and immunized via intramuscular injection into the hind leg. Immunizations were administered on days 0 and 14, with a dose of 3 μg mRNA-LNP. A negative control group received an equal volume of saline. Blood was collected and serum was separated on the 14th day after immunization. The specific antibody titer against the SARS-CoV2 virus S protein antigen was detected by ELISA, and the ICS antigen-specific cellular immunity test was performed on the 28th day. The results are shown in Figures 2, 3a and 3b. The LNP1, LNP5, LNP6, LNP10 and LNP11 experimental groups can all induce good humoral immunity and cellular immunity (wherein, the left side of each group in Figure 2 is the IgG antibody titer after one immunization, and the right side is the IgG antibody titer after two immunizations; the groups in Figures 3a and 3b are TNFα+, TNFγ+, IL2+, IL4+, and IL5+ from left to right, respectively).

[0348] Safety evaluation of 27 cholesterol cationic compounds

[0349] The SARS-CoV-2 antigen mRNA-LNP complex was inoculated intramuscularly into CD1 mice at a dose of 30 μg. The negative control group was injected with an equal volume of normal saline. The safety of the three-component LNP based on compound 1, compound 6, and compound 11 was evaluated by monitoring the systemic inflammatory factor IL-6 in the mice. As shown in Figure 4, after high-dose administration, the expression level of the systemic inflammatory factor IL-6 caused by the three-component LNP experimental group based on compound 1, compound 6, and compound 11 was significantly lower than that of the four-component LNP based on the marketed compound ALC-0315.

[0350] Example 28 Lyophilization Study of Cholesterol Cationic Lipid Compound Three-Component LNP

[0351] For example, the GFP-mRNA-LNP complex was dissolved in 20 mM Tris-sodium acetate (pH 7.5) buffer containing 10% sucrose by mass. 300 μL of the solution was aliquoted into 3 mL vials and freeze-dried. The freeze-drying procedure included a pre-freezing phase at -30°C for 2 hours, a desorption drying phase at 25°C for 1 hour, and a sublimation drying phase at -40°C for 2 hours and -20°C for 2 hours, with a vacuum pressure of ≤10 Pa throughout. The complex was stable at 2-8°C for 1 month. After reconstitution in sterile, enzyme-free water, the total amount of mRNA, free mRNA concentration, encapsulation efficiency, and mRNA integrity were measured.

[0352] Table 3 Changes in critical quality attributes of LNP before and after freeze-drying

[0353] The results are shown in Table 3. The stability (e.g., particle size, PDI, and encapsulation efficiency) of the three-component LNPs prepared from the lipid compounds provided by the present invention after lyophilization was significantly higher than that of the control group. The particle size change of the LNPs prepared from the lipid compounds provided by the present invention before and after lyophilization was less than 10 nm, and the change in encapsulation efficiency was within 6%. In contrast, the particle size of the LNPs in the control group increased by more than 10 nm after lyophilization, and the change in mRNA encapsulation efficiency was also greater than 10%.

[0354] Example 29 Atomization Study of Cholesterol Cationic Lipid Compound Three-Component LNP

[0355] Using GFP-mRNA-LNP complex, mRNA-LNP was atomized by a nebulizer and droplets were collected. The particle size, PDI and potential were measured using a nanoparticle size detector, and the content and encapsulation efficiency were measured using a Ribogreen detection kit.

[0356] Table 4 Key quality attribute parameters of LNP before and after atomization

[0357] The experimental results are shown in Table 4 and Figure 5. After atomization, the key quality attributes of LNP1, LNP4, LNP5 and LNP10 samples, such as particle size, PDI and encapsulation efficiency, changed little. After atomization, they still maintained a good particle state and the encapsulation efficiency changed by less than 10%. In comparison, the particle size of the LNP formulas of control groups 3 and 4 after atomization was close to 200nm, and the encapsulation efficiency also dropped to nearly 40%. The particle structure of the four-component LNP based on ALC-0315 in control group 5 was destroyed after atomization, and the encapsulation efficiency was even undetectable. The atomized samples were transfected into Hep3B cells, 500ng mRNA-LNP / 10 5 cells / well, and GFP expression levels were detected by microscopic imaging 24 hours later. The results are shown in Figure 6. The cell expression of the samples of the LNP formulas of the control groups 3 and 4 was weak after nebulization. The four groups of samples LNP1, LNP4, LNP5 and LNP10 still retained good cell transfection activity after nebulization, while there was no cell expression after nebulization of the four-component LNP.

[0358] Example 30 Expression in the lungs of mice after aerosol inhalation of LNP

[0359] By the operating procedures of Example 24, LNP4, LNP5, and LNP10 were used to encapsulate Luc mRNA. C57BL / 6 female mice aged 7-9 weeks were selected and 10 μg of Luc-mRNA-LNP complex was administered by atomization. After 6 hours of administration, the mice were anesthetized and intraperitoneally injected with fluorescent substrate. The mice were killed and dissected, and fluorescence imaging was performed on the heart, liver, spleen, lung, and kidney, respectively. The total fluorescence quantum number was calculated, and the results were shown in Figures 7a and 7b (wherein, LNP4, LNP5, and LNP10 were respectively used in each group of Figure 7b from left to right). After the mice were atomized and inhaled Luc-mRNA-LNP, very strong fluorescence expression was detected in the lungs. This shows that LNP4, LNP5, and LNP10 can achieve the selective expression of mRNA in the mouse lungs after atomization and inhalation, thus further illustrating that the three-component LNP based on cholesterol cationic lipid compounds we designed can be used in the application of atomized inhalation therapy of mRNA.

[0360] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Compound represented by formula (I) in, R1 is selected from -OR4, -NR4R5, -NR4C(=O)R5, -C(=O)OR5, -OC(=O)R5, -OC(=O)OR5, -CN, a nitrogen-containing heterocyclic group or a guanidine group; R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or C 3-8 Cycloalkynyl; G1 is selected from chemical bonds (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-9 Alkynylidene, C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene; Preferably, the number of consecutive carbon atoms in R1-G1- does not exceed 10; G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene, C 2-12 Alkynylidene, C 3-12 Cycloalkylene, C 3-12 Cycloalkenylene, C 3-12 Cycloalkynylene or C 6-12 arylene; L1 and L2 are each independently selected from a chemical bond (-), -O-, -S-, -O(C=O)O-, -(C=O)NR a -、-NR a (C=O)-, -O(C=O)-, -(C=O)O-, -SS-, -S(O) x -、-OS(O) x O-, -C(=O)S-, -SC(=O)-, -NR a C(=O)NR b -、-OC(=O)NR a -、-NR a C(=O)O-, -OC(=O)S-, -SC(=O)O-, -P(O)(OR a )O-、-OP(O)(OR a )O- or C 1-12 A combination of one or more of alkylene; x is selected from 0, 1 or 2; R a , R b Each independently selected from H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynes; R2 is selected from naturally occurring or non-naturally occurring steroids; R3 is selected from naturally occurring or non-naturally occurring steroids, C 6-24 Alkyl, C 6-24 Alkenyl, C 6-24 Alkyne or C 6-24 Alkoxy.

2. The compound according to claim 1, characterized in that The R1 is selected from -OR4, -NR4R5, pyrazolyl, imidazolyl, piperazinyl, alkylpiperazine, piperidinyl, alkylpiperidine, guanidinyl, pyrrolyl or pyrrolidinyl; the R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl or C 3-8 Cycloalkenyl; The G1 is a chemical bond (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene; Preferably, the G1 is C 1-6 Alkylene or -C 2-6 alkenylene; Preferably, the number of consecutive carbon atoms in R1-G1- does not exceed 10; The G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene or -C 2-12 Alkynylidene; The L1 and L2 are each independently selected from -O(C=O)-, -(C=O)O-, -SS-, -O(C=O)O-, -NR a C(= O)O-, -(C=O)NR a -、-NR a (C=O)-, -C(=O)S-, -SC(=O)-, -OC(=O)NR a - or C 1-12 A combination of one or more of alkylene; Among them, R a H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkyne.

3. The compound according to claim 1, characterized in that The R1 is selected from -OR4, -NR4R5, imidazolyl, piperazinyl or guanidinyl; The R4 and R5 are each independently selected from H, C 1-5 alkyl; The G1 is an unsubstituted C 1-6 Alkylene; Preferably, the number of consecutive carbon atoms in R1-G1- does not exceed 10; The G2 and G3 are each independently selected from a chemical bond (-), C 1-10 Alkylene; The L1 and L2 are each independently selected from -O-, -O(C=O)-, -O(C=O)O-, -(C=O)O-, -(C=O)S-, -NHC(=O)O-, -NHC(=O)-, 4. The compound according to claim 1, characterized in that The R2 is a sterol; Preferably, the sterol is an animal sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a plant sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a synthetic sterol, or an oxidized form or a reduced form thereof; More preferably, the sterol is selected from cholesterol, an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol; More preferably, the sterol is an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol; More preferably, the sterol is selected from avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprostanol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fucosterol, hexahydroluminosterol, hydroxycholesterol, lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid or lithocholic acid; More preferably, the structural formula of the sterol is as follows: Where R is C 1-20 alkyl.

5. The compound according to any one of claims 1 to 4, characterized in that The R3 is selected from: Preferably, said R3 is selected from:

6. The compound according to any one of claims 1 to 5, characterized in that The compound is selected from:

7. A lipid nanoparticle, characterized in that: The invention comprises the compound according to any one of claims 1 to 6.

8. The lipid nanoparticle according to claim 7, characterized in that Also included is a polyethylene glycol lipid and at least one helper lipid; wherein the helper lipid is selected from a neutral lipid, a zwitterionic lipid or an anionic lipid.

9. The lipid nanoparticle according to claim 8, characterized in that The polyethylene glycol lipid is selected from 2-[(polyethylene glycol)-2000]-N,N-tetracosyl acetamide (ALC-0159), 1,2-dimyristoyl-sn-glyceromethoxy polyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE) or PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA); The auxiliary lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), palmitoyloleoylphosphatidylcholine (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), phosphorylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearo ... -glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1,2-diacaproyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-eicosenoyl-sn-glycero-3-phosphocholine (DEPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), or lysophosphatidylethanolamine.

10. The lipid nanoparticle according to claim 8, characterized in that The molar ratio of the compound according to any one of claims 1 to 6: auxiliary lipid: polyethylene glycol lipid is 20-80:20-80:0.5-20; preferably, the molar ratio of the compound according to any one of claims 1 to 6: auxiliary lipid: polyethylene glycol lipid is 30-80:30-80:0.5-20.

11. The lipid nanoparticle according to claim 7, characterized in that It has a diameter of 15 nm to 300 nm.

12. Use of the compound according to claims 1-6 and / or the lipid nanoparticles according to claims 7-11 in preparing a delivery system for biologically active substances.

13. The use according to claim 12, characterized in that The bioactive substance is DNA or RNA, wherein the RNA is selected from antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA and self-replicating mRNA; Preferably, the bioactive substance delivery system is an mRNA vaccine; Preferably, the mRNA vaccine is a vaccine for preventing cancer, viral infection, bacterial infection, or fungal infection; Preferably, the virus is selected from Norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, coxsackie virus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, polio virus, rabies virus, rotavirus, and / or measles virus.

14. The lipid nanoparticle according to any one of claims 7 to 11, characterized in that Also contains biologically active substances.

15. The lipid nanoparticle according to claim 14, characterized in that The biologically active substance is DNA or RNA, wherein the RNA is preferably selected from antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA and self-replicating mRNA.

16. The lipid nanoparticle according to claim 14 or 15, characterized in that The nitrogen-to-phosphorus ratio of the lipid nanoparticles is (1-15):

1.

17. A drug, characterized in that The drug comprises the lipid nanoparticles according to any one of claims 14 to 16, and pharmaceutically acceptable excipients.

18. The drug according to claim 17, characterized in that The medicine is a liquid preparation or a freeze-dried powder.

19. The drug according to claim 17, characterized in that The medicine is an oral preparation, an intramuscular injection preparation, a subcutaneous injection preparation, an intravenous injection preparation, an aerosol inhalation preparation and / or a dry powder inhalation preparation.